[go: up one dir, main page]

MX2024001613A - Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo. - Google Patents

Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.

Info

Publication number
MX2024001613A
MX2024001613A MX2024001613A MX2024001613A MX2024001613A MX 2024001613 A MX2024001613 A MX 2024001613A MX 2024001613 A MX2024001613 A MX 2024001613A MX 2024001613 A MX2024001613 A MX 2024001613A MX 2024001613 A MX2024001613 A MX 2024001613A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
oxaspiro
derivative
oxaspiro derivative
Prior art date
Application number
MX2024001613A
Other languages
English (en)
Inventor
Zehong Wan
Jiaquan Feng
xinshan Deng
Original Assignee
Shujing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shujing Biopharma Co Ltd filed Critical Shujing Biopharma Co Ltd
Publication of MX2024001613A publication Critical patent/MX2024001613A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un derivado de oxaespiro y a su método de preparación y uso; específicamente, se proporcionan un compuesto representado por la fórmula general (I), un estereoisómero del mismo, un tautómero del mismo o una sal farmacéuticamente aceptable del mismo y un método de preparación del mismo, el uso del mismo para activar la actividad de un receptor opioide, y el uso del mismo en la preparación de un fármaco analgésico. (ver Fórmula).
MX2024001613A 2021-08-02 2022-08-01 Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo. MX2024001613A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110888850 2021-08-02
CN202110895052 2021-08-02
PCT/CN2022/109503 WO2023011422A1 (zh) 2021-08-02 2022-08-01 氧杂螺环类衍生物、制备方法及其用途

Publications (1)

Publication Number Publication Date
MX2024001613A true MX2024001613A (es) 2024-02-27

Family

ID=85154442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001613A MX2024001613A (es) 2021-08-02 2022-08-01 Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.

Country Status (11)

Country Link
US (1) US20240398772A1 (es)
EP (1) EP4375286A4 (es)
JP (1) JP7710599B2 (es)
KR (1) KR20240042486A (es)
CN (1) CN117751126A (es)
AU (1) AU2022322838B2 (es)
CA (1) CA3227380A1 (es)
IL (1) IL310506A (es)
MX (1) MX2024001613A (es)
TW (1) TW202321258A (es)
WO (1) WO2023011422A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675847B1 (en) 2003-10-01 2012-12-05 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
PL3290415T3 (pl) 2011-03-23 2021-07-19 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
US10442793B2 (en) * 2015-10-15 2019-10-15 Jiangsu Hengrui Medicine Co., Ltd Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
EP3722283A1 (en) * 2016-01-13 2020-10-14 Grünenthal GmbH 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CN109206417B (zh) * 2017-07-04 2023-01-03 四川海思科制药有限公司 阿片受体激动剂及其应用
US11124523B2 (en) 2017-10-13 2021-09-21 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
EP4092031A4 (en) * 2020-01-17 2024-02-21 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Azabicyclic substituted oxaspiro derivative, preparation method therefor and medical use thereof

Also Published As

Publication number Publication date
AU2022322838A1 (en) 2024-02-15
TW202321258A (zh) 2023-06-01
US20240398772A1 (en) 2024-12-05
CN117751126A (zh) 2024-03-22
WO2023011422A1 (zh) 2023-02-09
JP7710599B2 (ja) 2025-07-18
JP2024528181A (ja) 2024-07-26
CA3227380A1 (en) 2023-02-09
KR20240042486A (ko) 2024-04-02
EP4375286A1 (en) 2024-05-29
AU2022322838B2 (en) 2024-12-12
IL310506A (en) 2024-03-01
EP4375286A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
MX2024003295A (es) Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
UY32490A (es) Inhibidores de beta-secretasa
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX2022005732A (es) Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
MX2019010108A (es) Derivados de azetidina.
DOP2025000146A (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
MX2024001613A (es) Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias